NYSE:ZTS - Zoetis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$97.39 -0.59 (-0.60 %)
(As of 04/18/2019 10:14 AM ET)
Previous Close$97.98
Today's Range$97.37 - $99.20
52-Week Range$77.00 - $103.33
Volume6,943 shs
Average Volume2.32 million shs
Market Capitalization$46.67 billion
P/E Ratio31.38
Dividend Yield0.67%
Beta0.93
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.6696 per share
Book Value$4.55 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$46.67 billion
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable

Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Wednesday, February 13th. Stockholders of record on Thursday, April 18th will be paid a dividend of $0.164 per share on Monday, June 3rd. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Wednesday, April 17th. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis declared that its Board of Directors has approved a stock repurchase plan on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its shares are undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings results on Thursday, February, 14th. The company reported $0.79 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.02. The firm earned $1.56 billion during the quarter, compared to analysts' expectations of $1.53 billion. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The company's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm earned $0.69 EPS. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Zoetis.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $3.42-3.52 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.44. The company issued revenue guidance of $6.175-6.30 billion, compared to the consensus revenue estimate of $6.22 billion.Zoetis also updated its FY 2019 guidance to $3.42-3.52 EPS.

What price target have analysts set for ZTS?

14 analysts have issued twelve-month target prices for Zoetis' stock. Their forecasts range from $86.00 to $112.00. On average, they anticipate Zoetis' share price to reach $100.6154 in the next year. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

What are Wall Street analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:
  • 1. According to Zacks Investment Research, "Zoetis continues to maintain momentum on the back of growth from new parasiticide products (Simparica and Stronghold Plus), vaccines, strong dermatology portfolio and the addition of the Abaxis diagnostics portfolio. The company’s companion animal business has been performing well. The Abaxis acquisition has strengthed the company’s presence in the animal health diagnostics market, a fast-growing portion of the animal health industry which should further boost sales. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Such outbreaks may hurt regional or global sales of particular animal-derived food products or result in reduced exports of the same, due to either heightened export restrictions or import prohibitions, in turn, dampening demand for livestock products. Shares of Zoetis have outperformed the industry in the past year. Estimates are stable ahead of the Q4 results." (2/16/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for ZTS shares to $105 from $98. The increase in our PT is driven by multiple expansion. Given the company’s durable business model and the positive outlook for macro factors, we think ZTS’s multiple will hold and upwards earnings revisions should drive shares higher. We think ZTS’s multiple will be supported by: 1) its durable business model, 2) positive outlook for macro factors, and 3) solid execution by management. Upwards earnings revisions could come from: 1) higher-than- anticipated peak sales for new launches, 2) better-than-expected operating margins in 2018+, and 3) M&A." (10/17/2018)

Has Zoetis been receiving favorable news coverage?

Media headlines about ZTS stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Hexavest Inc. (0.08%), DAVENPORT & Co LLC (0.07%), Nisa Investment Advisors LLC (0.06%), Gofen & Glossberg LLC IL (0.06%), Heritage Investors Management Corp (0.05%) and Retirement Systems of Alabama (0.05%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, First Citizens Bank & Trust Co., State of Alaska Department of Revenue, Heritage Investors Management Corp, Argus Investors Counsel Inc., Town & Country Bank & Trust CO dba First Bankers Trust CO, Daiwa SB Investments Ltd. and Gofen & Glossberg LLC IL. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., Ferguson Wellman Capital Management Inc., Pacer Advisors Inc., BTIM Corp., Mercer Global Advisors Inc. ADV, Park National Corp OH, Bell Asset Management Ltd and Nisa Investment Advisors LLC. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $97.98.

How big of a company is Zoetis?

Zoetis has a market capitalization of $46.95 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  636 (Vote Outperform)
Underperform Votes:  399 (Vote Underperform)
Total Votes:  1,035
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel